Topiramate and Schizophrenia: Effects on Weight and Psychopathology
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Clozapine is the sole AP agent with superiority in treatment refractory schizophrenia, but it
also is associated with the greatest risk of weight gain and other metabolic abnormalities.
Topiramate, an anticonvulsant agent, possesses a weight-reducing effect. Furthermore, some
studies have suggested that Topiramate may be associated with improvements in psychopathology
in treatment refractory schizophrenia. Here the investigators propose to determine the role
of topiramate for augmentation purposes (psychopathology) and as an adjunctive
pharmacological intervention for weight loss in overweight/obese individuals with
Ultra-Treatment Resistant Schizophrenia or Schizoaffective disorder taking clozapine.